<DOC>
	<DOCNO>NCT01282281</DOCNO>
	<brief_summary>Background : Most psychotropic medication effective treatment Bipolar Disorder ( BD ) associate endocrine-metabolic change ( EMCs ) . To date , long-term study BD examine specifically association inflammation EMCs BD . Specific aim : 1 ) identify predictor EMCs among adolescent adult BD start medication ; 2 ) compare change EMCs youth adult treat BD ; 3 ) measure change EMCs associate use different medication BD . Research Design : Participants : 30 adolescent ( 14-18 year old ) BD 30 adult ( 19-65 year old ) BD . Measures : Blood level biomarkers associate EMCs measure .</brief_summary>
	<brief_title>Prospective Metabolic Monitoring Youth Adults With Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Diagnosis BD type I , II , NOS determine DSMIV diagnostic criterion ( confirm use SCID KSADS ) 3 . Both female male , age14 65 year 4 . Decision physician patient initiate pharmacotherapy traditional mood stabilizer atypical antipsychotic 5 . Able understand comply requirement study 6 . Proficient English . 1 . A primary psychiatric disorder bipolar disorder I , II NOS ( comorbid Axis I II disorder permit , long clinician judge bipolar disorder primary condition ) 2 . Initiation antipsychotic , mood stabilizer medication know endocrinemetabolic effect within 4 week prior baseline visit 3 . Patients , investigator opinion , unlikely adhere pharmacotherapy least 4 week baseline visit 4 . Significant medical condition would contraindicate use mood stabilizer atypical antipsychotic 5 . Patients receive pharmacological treatment diabetes mellitus ( DM ) , hyperlipidemia , obesity 6 . Acute chronic medical illness ( e.g . urinary tract infection , bronchitis , rheumatoid arthritis ) , judge investigator , would significantly alter inflammatory , metabolic , endocrine index 7 . Screening bloodwork identifies clinically significant deviation reference range clinical laboratory test result , judged investigator .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Youth</keyword>
	<keyword>Adults</keyword>
	<keyword>Endocrine-metabolic change</keyword>
</DOC>